Cara Therapeutics Inc. (CARA) announced Wednesday morning that its Phase 2/3 trial of I.V. CR845 in patients undergoing abdominal surgeries demonstrated statistically significant reductions in pain intensity compared to placebo.
from RTT - Before the Bell https://ift.tt/2Iy94pW
via IFTTT
No comments:
Post a Comment